 ATLANTA--BUSINESS WIRE--- VIRI Biotech--Virios Therapeutics, Inc. Nasdaq: VIRI, a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its third quarter 2022 financial results will be reported on Monday, November 14, 2022 before the open of the financial markets. 